IBDEI1KU ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,25203,1,3,0)
 ;;=3^Inflammatory Liver Disease,Oth Spec
 ;;^UTILITY(U,$J,358.3,25203,1,4,0)
 ;;=4^K75.89
 ;;^UTILITY(U,$J,358.3,25203,2)
 ;;=^5008829
 ;;^UTILITY(U,$J,358.3,25204,0)
 ;;=K76.4^^107^1214^21
 ;;^UTILITY(U,$J,358.3,25204,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25204,1,3,0)
 ;;=3^Peliosis Hepatis
 ;;^UTILITY(U,$J,358.3,25204,1,4,0)
 ;;=4^K76.4
 ;;^UTILITY(U,$J,358.3,25204,2)
 ;;=^91041
 ;;^UTILITY(U,$J,358.3,25205,0)
 ;;=K71.50^^107^1214^25
 ;;^UTILITY(U,$J,358.3,25205,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25205,1,3,0)
 ;;=3^Toxic Liver Disease w/ Chronic Active Hepatitis w/o Ascites
 ;;^UTILITY(U,$J,358.3,25205,1,4,0)
 ;;=4^K71.50
 ;;^UTILITY(U,$J,358.3,25205,2)
 ;;=^5008799
 ;;^UTILITY(U,$J,358.3,25206,0)
 ;;=K71.51^^107^1214^26
 ;;^UTILITY(U,$J,358.3,25206,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25206,1,3,0)
 ;;=3^Toxic Liver Disease w/ Chronic Active Hepatitis w/ Ascites
 ;;^UTILITY(U,$J,358.3,25206,1,4,0)
 ;;=4^K71.51
 ;;^UTILITY(U,$J,358.3,25206,2)
 ;;=^5008800
 ;;^UTILITY(U,$J,358.3,25207,0)
 ;;=K71.7^^107^1214^29
 ;;^UTILITY(U,$J,358.3,25207,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25207,1,3,0)
 ;;=3^Toxic Liver Disease w/ Fibrosis & Cirrhosis of Liver
 ;;^UTILITY(U,$J,358.3,25207,1,4,0)
 ;;=4^K71.7
 ;;^UTILITY(U,$J,358.3,25207,2)
 ;;=^5008802
 ;;^UTILITY(U,$J,358.3,25208,0)
 ;;=K71.8^^107^1214^33
 ;;^UTILITY(U,$J,358.3,25208,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25208,1,3,0)
 ;;=3^Toxic Liver Disease w/ Oth Disorders of Liver
 ;;^UTILITY(U,$J,358.3,25208,1,4,0)
 ;;=4^K71.8
 ;;^UTILITY(U,$J,358.3,25208,2)
 ;;=^5008803
 ;;^UTILITY(U,$J,358.3,25209,0)
 ;;=K71.9^^107^1214^34
 ;;^UTILITY(U,$J,358.3,25209,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25209,1,3,0)
 ;;=3^Toxic Liver Disease,Unspec
 ;;^UTILITY(U,$J,358.3,25209,1,4,0)
 ;;=4^K71.9
 ;;^UTILITY(U,$J,358.3,25209,2)
 ;;=^5008804
 ;;^UTILITY(U,$J,358.3,25210,0)
 ;;=K75.2^^107^1214^20
 ;;^UTILITY(U,$J,358.3,25210,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25210,1,3,0)
 ;;=3^Nonspecific Reactive Hepatitis
 ;;^UTILITY(U,$J,358.3,25210,1,4,0)
 ;;=4^K75.2
 ;;^UTILITY(U,$J,358.3,25210,2)
 ;;=^5008826
 ;;^UTILITY(U,$J,358.3,25211,0)
 ;;=K75.3^^107^1214^13
 ;;^UTILITY(U,$J,358.3,25211,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25211,1,3,0)
 ;;=3^Granulomatous Hepatitis NEC
 ;;^UTILITY(U,$J,358.3,25211,1,4,0)
 ;;=4^K75.3
 ;;^UTILITY(U,$J,358.3,25211,2)
 ;;=^5008827
 ;;^UTILITY(U,$J,358.3,25212,0)
 ;;=K76.6^^107^1214^22
 ;;^UTILITY(U,$J,358.3,25212,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25212,1,3,0)
 ;;=3^Portal Hypertension
 ;;^UTILITY(U,$J,358.3,25212,1,4,0)
 ;;=4^K76.6
 ;;^UTILITY(U,$J,358.3,25212,2)
 ;;=^5008834
 ;;^UTILITY(U,$J,358.3,25213,0)
 ;;=F20.3^^107^1215^31
 ;;^UTILITY(U,$J,358.3,25213,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25213,1,3,0)
 ;;=3^Undifferentiated/Atypical Schizophrenia
 ;;^UTILITY(U,$J,358.3,25213,1,4,0)
 ;;=4^F20.3
 ;;^UTILITY(U,$J,358.3,25213,2)
 ;;=^5003472
 ;;^UTILITY(U,$J,358.3,25214,0)
 ;;=F20.9^^107^1215^27
 ;;^UTILITY(U,$J,358.3,25214,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25214,1,3,0)
 ;;=3^Schizophrenia,Unspec
 ;;^UTILITY(U,$J,358.3,25214,1,4,0)
 ;;=4^F20.9
 ;;^UTILITY(U,$J,358.3,25214,2)
 ;;=^5003476
 ;;^UTILITY(U,$J,358.3,25215,0)
 ;;=F31.9^^107^1215^6
 ;;^UTILITY(U,$J,358.3,25215,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25215,1,3,0)
 ;;=3^Bipolar Disorder,Unspec
